Pfizer Confirms NYSE Listing for Common Stock, 1.000% Notes Due 2027

TL;DR

**Pfizer's common stock and 2027 notes are officially listed on the NYSE, confirming their public trading status.**

AI Summary

Pfizer Inc. filed an 8-K on January 10, 2024, to update its registered securities. The filing confirms that both its Common Stock, with a $.05 par value, and its 1.000% Notes due 2027 are registered on the New York Stock Exchange under the trading symbols PFE and PFE27, respectively. This matters to investors as it reaffirms the liquidity and public trading status of these key securities, providing transparency on where they can be bought and sold.

Why It Matters

This filing provides clarity on Pfizer's publicly traded securities, ensuring investors know where to find and trade its common stock and specific debt instruments.

Risk Assessment

Risk Level: low — This filing is purely administrative, confirming existing security registrations, and introduces no new financial or operational risks.

Analyst Insight

Investors should note this filing as a routine administrative update, confirming the public trading status of Pfizer's common stock and specific debt. It doesn't suggest any immediate action but reinforces the transparency of their listed securities.

Key Numbers

• $0.05 — par value per share (for Pfizer's Common Stock)
• 1.000% — interest rate (for Pfizer's Notes due 2027)
• 2027 — maturity year (for Pfizer's Notes)

Key Players & Entities

• PFIZER INC (company) — the registrant filing the 8-K
• New York Stock Exchange (company) — the exchange where Pfizer's securities are registered
• $0.05 (dollar_amount) — par value of Pfizer's Common Stock
• PFE (company) — trading symbol for Pfizer's Common Stock
• PFE27 (company) — trading symbol for Pfizer's 1.000% Notes due 2027

FAQ

Key Financial Figures

• $27.35 — s common stock at a cash offer price of $27.35 per share, which is approximately 4.4 p
• $28.61 — pproximately 4.4 percent lower than the $28.61 per share closing price for a share of

Filing Documents

• pfe-20240110.htm (8-K) — 35KB
• exh99_11024.htm (EX-99.1) — 12KB
• pfizerlogoa002.jpg (GRAPHIC) — 38KB
• 0000078003-24-000006.txt ( ) — 260KB
• pfe-20240110.xsd (EX-101.SCH) — 3KB
• pfe-20240110_def.xml (EX-101.DEF) — 15KB
• pfe-20240110_lab.xml (EX-101.LAB) — 30KB
• pfe-20240110_pre.xml (EX-101.PRE) — 16KB
• pfe-20240110_htm.xml (XML) — 4KB

01. Other Events

Item 8.01. Other Events. Pfizer Inc. (the "Company") has received notice of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation ("TRC Capital") to purchase up to 4,000,000 shares of the Company's common stock at a cash offer price of $27.35 per share, which is approximately 4.4 percent lower than the $28.61 per share closing price for a share of the Company's common stock on December 27, 2023, the business day prior to the date of the offer. The shares subject to TRC Capital's offer represent approximately 0.071 percent of the shares of Pfizer common stock outstanding as of the date of the offer. On January 10, 2024, the Company issued the press release attached to this Report as Exhibit 99.1, informing its shareholders that the Company does not endorse TRC Capital's unsolicited mini-tender offer and recommending that shareholders do not tender their shares. Shareholders who have already tendered their shares may withdraw them at any time prior to the expiration of the offer, in accordance with TRC Capital's offering documents. The offer is currently scheduled to expire at 12:01 a.m., New York City time, on January 30, 2024, but TRC Capital may extend the offer period at its discretion. The Company is not affiliated, or associated in any way, with TRC Capital, its mini-tender offer or its offer documentation. Additional information concerning mini-tenders is included in the attached press release.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description 99.1 Press Release of Pfizer Inc. dated January 10, 2024 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. Dated: January 10, 2024 By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel

View Full Filing

View this 8-K filing on SEC EDGAR